Impact of MK-0954A on Uric Acid in the Management of Hypertension (MK-0954A-366)

Inclusion criteria: * Participant was \>20 years and \<75 years of age on the index date (i.e., the date of initiating MK-0954A therapy) * Diagnosed with hypertension and had received MK-0954A 50/12.5 mg for at least 3 months * Had at least one serum uric acid measurements at baseline and one at 3 months after using MK-0954A 50/12.5 mg * Had the following records documented in the chart during the data collection period: * medical history and co-morbidities (if available) * sitting blood pressure, serum uric acid, lipid profile test results before and after using MK-0954A 50/12.5 mg * serum electrolytes, serum creatinine, and pre-meal sugar (if available) * prescription information of all antihypertensive regimens Exclusion criteria: * Had been treated with diuretic or angiotensin-receptor blockers (ARBs) 2 weeks before initiated treatment with MK-0954A 50/12.5 mg * Serum creatinine \>2 mg/dL